Targeting Lung Cancer Stem Cells: Research and Clinical Impacts
Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012. Non-small cell lung cancer (NSCLC), which is one of two types of lung cancer, accounts for 85–90% of all lung cancers. Despite advances in therapy, lung cancer still remains a lea...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media
2017
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/37242/ http://eprints.usm.my/37242/1/%28Targeting_Lung_Cancer_Stem%29_fonc-07-00080.pdf |
| Summary: | Lung cancer is the most common cancer worldwide, accounting for 1.8 million new
cases and 1.6 million deaths in 2012. Non-small cell lung cancer (NSCLC), which is one
of two types of lung cancer, accounts for 85–90% of all lung cancers. Despite advances
in therapy, lung cancer still remains a leading cause of death. Cancer relapse and dissemination
after treatment indicates the existence of a niche of cancer cells that are not
fully eradicated by current therapies. These chemoresistant populations of cancer cells
are called cancer stem cells (CSCs) because they possess the self-renewal and differentiation
capabilities similar to those of normal stem cells. Targeting the niche of CSCs in
combination with chemotherapy might provide a promising strategy to eradicate these
cells. Thus, understanding the characteristics of CSCs has become a focus of studies
of NSCLC therapies. |
|---|